Neuroblastoma and Dendritic Cell Function

Seminars in Pediatric Surgery

Volumn 13, Issue 1, 2004, Pages 61-71

  Redlinger Jr , Richard E ^a   Mailliard, Robbie B ^a   Barksdale Jr , Edward M ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GM3; INTERLEUKIN 12; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL MATURATION; CELL POLARITY; CELL STRUCTURE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; GENE FUNCTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOBIOLOGY; NATURAL KILLER CELL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TUMOR REJECTION; VACCINATION;

EID: 1242343577     PISSN: 10558586     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2003.09.009     Document Type: Article

References (82)

1. Young JL, Ries LG, Silverberg E, et al: Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58:598-602. 1986
2. Nagabuchi E, Ziegler MM: Neuroblastoma, in Oldham KT, Colombani PM, Foglia RP (eds): Surgery of Infants and Children: Scientific Principles and Practice. Philadelphia, PA, Lippincott-Raven, 1997, pp 593-613
3. Grosfeld JL, Rescorla FJ, West KW, et al: Neuroblastoma in the first year of life: Clinical and biological factors influencing outcome. Semin Pediatr Surg 2:37-46, 1993
4. 2 Microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res 50:3694-3700, 1990
5. Hank JA, Robinson RR, Surfus J, et al: Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50:5234-5239, 1990
6. Rueda F, Marti F, Pardo N, et al: Interleukin-2 in neuroblastoma: Clinical perspectives based on biological studies. Cancer Biother Radiopharm 11:303-308, 1996
7. Coze C, Aalto-Setala K, Brenner M, et al: Characteristics and immunomodulatory properties of human neuroblastoma cells after retrovirus-mediated gene transfer of the cytokine genes IL-2 and IFN-gamma. Transgenics 1:585-595, 1995
8. Ucar K, Seeger RC, Challita PM, et al: Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector. Cancer Gene Ther 2:171-181, 1995
9. Cheung NKV, Saarinen UM, Neely JE, et al: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 45:2642-2649, 1985
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: Morphology, quantification, tissue distribution. J Exp Med 137:1142-1162, 1973
11. Dubois B, Vanbervliet B, Fayette J, et al: Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. J Exp Med 185:941-951, 1997
12. Steinman RM: The dendritic system and its role in immunogenicity. Ann Rev Immunol 9:271-296, 1991
13. Fernandez NC, Lozier A, Flamaent C, et al: Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405-411, 1999
14. Ardavin C, Wu L, Li C, et al: Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362:761-763, 1993
15. Suss G, Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand induced apoptosis. J Exp Med 183:1789-1796, 1996
16. Caux C, Vandervliet B, Massacrier C, et al: CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+ TNFa. J Exp Med 184:695-706, 1996
17. Inaba K, Inaba M, Naito M, et al: Dendritic cell progenitors phagocytose particulates, including Bacillus Calmette-Guerin organisms, and sensitize mice to myobacterial antigens in vivo. J Exp Med 178:479-488. 1993
18. Sallusto F, Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor α. J Exp Med 179:1109-1118, 1994
19. Jiang W, Swiggard WJ, Heufler C, et al: The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151-155, 1995
20. Young JW, Steinman RM: The hematopoietic development of dendritic cells. A distinct pathway for myeloid differentiation. Stem Cells 14:376-387, 1996
21. Avigan D: Dendritic cells: Development, function and potential use for cancer immunotherapy. Blood Rev 13:51-64, 1999
22. Tang A, Amagai M, Granger LG, et al: Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 361:82-85, 1993
23. Roake JA, Rao AS, Morris PJ, et al: Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin I. J Exp Med 181:2237-2247, 1995
24. Dieu MC, Vandervliet B, Vicari A, et al: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188:373-386, 1998
25. Sozzani S, Allavena P, D'Amico G, et al: Cutting edge: Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties. J Immunol 161:1083-1086. 1998
26. Adema GJ, Hartgers F, Verstraten R, et al: A dendritic cell-derived C-C chemokine that preferentially attracts naïve T cells. Nature 387:713-717, 1997
27. Kitajima T, Arizumi K, Bergstresser PR, et al: A novel mechanism of glucocorticoid-induced immune suppression: The inhibition of T cell-mediated terminal maturation of a murine dendritic cell line. J Clin Invest 98:142-147, 1996
28. Young JW, Kouliva L, Soergel SA, et al: The B7/BBI antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest 90:229-237, 1992
29. Van Voorhis WC, Valinsky J, Hoffman E, et al: Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158:174-191, 1983
30. Cassell DJ, Schwartz RH: A quantitative analysis of antigen presenting cell function: Activated B cells stimulate naïve CD4 T cells but are inferior to DC in providing costimulation. J Exp Med 180:1829-1840, 1994
31. Ellis J, Chain BM, Davies DH, et al: Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL)-2, IL-4 and interferon gamma by allogeneic T cells. Eur J Immunol 21:2803-2809, 1991
32. Bhardwaj N, Friedman SM, Cole BC, et al: Dendritic cells are potent antigen presenting cells for microbial superantigens. J Exp Med 166:182-194, 1992
33. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 392:245-252, 1998
34. Cella M, Scheidegger D, Palmer-Lehmann K, et al: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184:747-752, 1996
35. Bhardwaj N, Seder RA, Reddy A, et al: IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest 98:715-722, 1996
36. Macatonia SE, Hosken NA, Litton M, et al: Dendritic cells produce IL-12 and direct the development of Th1 cells from naïve CD4+ cells. J Immunol 154:5071-5079, 1995
37. Ferlazzo G, Tsang ML, Moretta L, et al: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195:343-351, 2002
38. Esche C, Lokshin A, Shurin GV, et al: Tumors other immune targets: Dendritic cells. J Leukoc Biol 66:336-344, 1999
39. Toriyama K, Wen DR, Pauel E, et al: Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Derm 100:269S-273S, 1993
40. Zeid NA, Muller HK: S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25:338-343, 1993
41. Josien R, Li HL, Ingulli E, et al: TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191:495-502, 2000
42. L increases their resistance to prostate-cancer-induced apoptosis and antitumor effect in mice. J Immunol 165:1956-1964, 2000
43. Barksdale EM, Shurin GV, Lotze MT: Dendritic cells: Potential targets for immunotherapy of neuroblastoma. Program and Abstracts of the British Association of Pediatric Surgery, XLVII Annual International Congress. Sorrento, Italy, BAPS, 2000 (abstract)
44. Kanto T, Kalinski P, Hunter OC, et al: Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 167:3773-3784, 2001
45. Halliday WJ, Koppi TA, Khan JM, et al: Leukocyte adherence inhibition: Tumor specificity of cellular and serum-blocking reactions in human melanoma, breast cancer and colorectal cancer. J Natl Cancer Inst 65:327-335, 1980
46. Bugis SP, Lotzova E, Savage HE, et al: Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 31:176-181, 1990
47. Thurnher M, Radamayar C, Ramoner R, et al: Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 67:1-7, 1996
48. Sietsma H, Nijhof W, Dontje B, et al: Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res 58:4840-4804, 1998
49. Lahn M, Kunzmann R, Kohler G, et al: Comparison of cytogenetics, cytokine secretion and oncogene expression in primary cultures of renal carcinoma cells. Oncology 54:429-437, 1997
50. Klagsbrun M, Soker S: VEGF/VEPF: The angiogenic factor found? Curr Biol 3:699-702, 1993
51. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
52. Eggert A, Ikegaki N, Kwiatkowski J, et al: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900-1908, 2000
53. Fakhari M, Pullirsch D, Paya K, et al: Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 37:582-587, 2002
54. Beierle EA, Strande LF, Chen MK: VEGF upregulates BCL-2 expression and is associated with decreased apoptosis in neuroblastoma cells. J Pediatr Surg 37:467-471, 2002
55. Lissoni P, Malugani F, Bonfanti A, et al: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 15:140-144, 2001
56. Cohen PS, Letterio JJ, Gaetano C, et al: Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res 55:2380-2386, 1995
57. Massague J: The transforming growth factor-beta family. Ann Rev Cell Biol 6:597-641, 1990
58. Sporn M, Roberts RA: Transforming growth factor-beta: Recent progress and new challenges. J Cell Biol 119:1017-1022, 1992
59. 1 and interleukin-10. Blood 15:2992-2998, 2001
60. Saito M: Bioactive gangliosides: Differentiation inducers for hematopoietic cells and their mechanism(s) of actions. Adv Lipid Res 25:303-327, 1993
61. Ladisch S: Tumor cell gangliosides. Adv Pediatr 34:45-58, 1987
62. Wu ZL, Schwartz E, Seeger R, et al: Expression of GD2 ganglioside by untreated primary human neuroblastoma. Cancer Res 46:440-443, 1986
63. Ladisch S, Wu ZL, Feig S, et al: Shedding of GD2 ganglioside by human neuroblastoma. Int J Cancer 39:73-76, 1987
64. Ladisch S, Kitada S, Hays EF: Gangliosides shed by tumor cells enhance tumor formation in mice. Cancer Res 43:3808-3813, 1983
65. Li R, Villacreses N, Ladisch S: Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 55:211-214, 1995
66. McKallip R, Li R, Ladisch S: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163:3718-3726, 1999
67. Shurin GV, Shurin MR, Bykovskaia S, et al: Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61:363-369, 2001
68. Palucka K, Banchereau J. Dendritic cells: A link between innate and adaptive immunity. J Clinical Immunol 19:12-23, 1999
69. Shimizu T, Berhanu A, Redlinger RE, et al: Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. J Pediatr Surg 36:1285-1292, 2001
70. Redlinger RE, Shimizu T, Remy T, et al: Cellular mechanisms of interleukin-12-mediated neuroblastoma regression. J Pediatr Surg 38:199-204, 2003
71. Zitvogel L, Couderc B, Mayordomo JI, et al: IL-12 engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci 795:284-293, 1996
72. Lampson LA, Fischer CA: Weak HLA and beta2-microglobulin expression of neuronal cell lines can be modulated by interferon. Proc Natl Acad Sci USA 81:6476-6480, 1984
73. Redlinger RE, Mailliard RB, Barksdale EM: Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy. J Pediatr Surg 38:857-862, 2003
74. Vieira PL, de Jong EC, Wierenga EA, et al: Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 164:4507-4512, 2000
75. Kapsenberg ML, Hilkens CMU, van der Pouw Kraan TC, et al: Atopic allergy: A failure of antigen-presenting cells to properly polarize helper T cells? Am J Respir Crit Care Med 162:S76-S80, 2000
76. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 52-58, 1996
77. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate regression. Cancer Res 61:8513-8519. 2001
78. Orentas RJ, Schauer P, Bin Q, et al: Electrofushion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 213:4-13, 2001
79. Tatsumi T, Kierstead LS, Ranieri E, et al: Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619-628, 2002
80. Kalinski P, Hilkens CM, Wierenga EA, et al: T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 20:561-567. 1999
81. Mailliard RB, Egawa S, Cal Q, et al: Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: Helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med 195:473-483, 2002
82. Mailliard RB, Son Y, Redlinger R, et al: Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol 171:2366-2373, 2003